SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company
SL Science Holding management rang the Nasdaq bell on September 2, 2026 to mark its first quarter as a public company, capping a period that began with its June 15, 2026 listing via business combination with Horizon Space Acquisition II Corp. Its Orphan Drug Designation request for Vdelta2+ γδT cells in glioblastoma multiforme (DRU-2026-11528) has been under FDA review since March 2026, and the company is still preparing additional nonclinical data requested by the agency — meaning the designation is not yet granted.
Key figures
- Drug Name
- Vdelta2+ γδT cells (glioblastoma multiforme)
- Phase Of Trial
- Preclinical (ODD request stage, no clinical trial disclosed)
- Dmf status
- DMFs filed for both γδT cells and γδT-derived exosomes
- Listing date
- June 15, 2026
- Odd tracking number
- DRU-2026-11528
- Fda review ongoing since
- March 2026
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.